[Autoimmune hemolytic anemia induced by mefenamic acid]

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Autoimmunohemolytic anemia is a serious condition where the immune system attacks red blood cells.
• Mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), has been rarely associated with immune-mediated adverse effects.

Observation:

• This case report details a patient who developed autoimmunohemolytic anemia after receiving mefenamic acid therapy.
• Immunological investigations revealed the presence of a free anti-erythrocytic antibody of the immunoglobulin G (IgG) class in the patient's serum.

Findings:

• The same IgG antibody was detected in an eluate prepared from the patient's own red blood cells.
• No specific blood group antigen was identified as the target for the antibody.
• Inhibition and facilitation tests excluded the direct involvement of mefenamic acid in the antibody-erythrocyte binding mechanism.

Implications:

• This case highlights a potential mechanism for drug-induced immune hemolytic anemia.
• Understanding the immunopathogenesis is crucial for accurate diagnosis and management of similar adverse drug reactions.
• Further research may elucidate the specific interactions leading to antibody formation against red blood cells in response to mefenamic acid.